ResearcherFondazione IRCCS Istituto Nazionale dei TumoriActive in the last 2 years
Sara Pusceddu
Matched on ORCID iD 0000-0002-5096-660X; OpenAlex author ID A5040559926. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 2 papers
Papers 4
- NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1001/jamanetworkopen.2023.50756↗
- Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. Co-author DOI 10.1002/cam4.70393↗
- Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and … Co-author DOI 10.3390/cancers11040484↗
- The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review. Last author DOI 10.1007/s11523-018-0567-0↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Federico Nichetti · 4 shared papers, 2018–2024 · strength 0.49
- Paper NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer:… DOI 10.1001/jamanetworkopen.2023.50756↗
- Paper Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. DOI 10.1002/cam4.70393↗
- Paper The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Revi… DOI 10.1007/s11523-018-0567-0↗
- Monica Niger · 3 shared papers, 2019–2024 · strength 0.41
- Paper NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer:… DOI 10.1001/jamanetworkopen.2023.50756↗
- Paper Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. DOI 10.1002/cam4.70393↗
- Paper Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pan… DOI 10.3390/cancers11040484↗
- Vincenzo Mazzaferro · 2 shared papers, 2024 · strength 0.33
- Giuseppe Leoncini · 1 shared paper, 2024 · strength 0.15
- Federica Perrone · 1 shared paper, 2024 · strength 0.15
- Fausto Petrelli · 1 shared paper, 2019 · strength 0.08
- Gianluca Tomasello · 1 shared paper, 2019 · strength 0.08
- Michele Ghidini · 1 shared paper, 2019 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.